Valuation
- Market cap
- 216,187,000
- Revenue TTM
- $0
- Net income TTM
- $-167,500,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 10,919,700
- Avg volume
- 1,930,868
- Day's range
- $4.46 – $4.53
- Shares out
- 48,364,000
- Stochastic %K
- 17%
- Beta
- 0.30
- Analysts
- Hold
- Price target
- $6.00
Company profile
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, focused on designing, engineering, and developing potentially curative cell therapies for cancer patients in the United States. The company develops CRG-023, a tri-specific CAR T product candidate which is in phase 1 that targets tumor cells with three B-cell malignancies; and allogeneic platform, a universal vector solution designed to effectively lim...
Show more
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, focused on designing, engineering, and developing potentially curative cell therapies for cancer patients in the United States. The company develops CRG-023, a tri-specific CAR T product candidate which is in phase 1 that targets tumor cells with three B-cell malignancies; and allogeneic platform, a universal vector solution designed to effectively limit immune-based rejection to enable durable response of CAR T-cell therapy. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is based in San Carlos, California. As of August 18, 2025, CARGO Therapeutics, Inc. operates as a subsidiary of Concentra Biosciences, LLC.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 650 379 6143
- Website
- https://cargo-tx.com
- Address
- 835 Industrial Road, Suite 400, San Carlos, United States
Latest news
No headlines yet.
